| 高铜拴,于 哲,蔡 丹,谢 飞,王 健,张明华.重组人血管内皮抑素用于骨肉瘤术后化疗的疗效及对VEGF、PCNA、PTEN的影响[J].,2018,(21):4091-4094 |
| 重组人血管内皮抑素用于骨肉瘤术后化疗的疗效及对VEGF、PCNA、PTEN的影响 |
| Efficacy of Recombinant Human Endostatin in Postoperative Chemotherapy for Osteosarcoma and Its Effects on VEGF, PCNA, PTEN |
| 投稿时间：2018-02-28 修订日期：2018-03-25 |
| DOI：10.13241/j.cnki.pmb.2018.21.019 |
| 中文关键词: 重组人血管内皮抑素 骨肉瘤 术后化疗 肢体功能 |
| 英文关键词: rh-endostatin Osteosarcoma Postoperative chemotherapy Limb function |
| 基金项目:陕西省科技攻关项目(2008K1102） |
|
| 摘要点击次数: 301 |
| 全文下载次数: 110 |
| 中文摘要: |
| 摘要 目的：研究重组人血管内皮抑素用于骨肉瘤术后化疗的疗效及对血管内皮生长因子（VEGF）、增殖细胞核抗原（PCNA）、第10染色体丢失的磷酸酶（PTEN）的影响。方法：收集2014年3月至2016年3月我院的220例骨肉瘤患者，按抽签法分为实验组和对照组，每组各110例。对照组采用DIA化疗方案治疗，静脉滴注顺铂、异环磷酰胺、阿霉素。实验组在对照组基础上，采用重组人血管内皮抑素治疗，每次15 mg静脉滴注。两组均治疗2个疗程。对比两组治疗疗效，肢体功能评价，VEGF、PTEN水平，PCNA阳性表达率，不良反应发生率。结果：实验组总有效率显著高于对照组[81.81%（90/110）vs65.45%（72/110）]（P＜0.05）；实验组肢体功能优良率显著高于对照组[79.09%（87/110）vs63.63%（70/110）]（P＜0.05）；两组PTEN水平较治疗后显著升高，但无差异（P＞0.05），两组VEGF水平较治疗后显著降低，且实验组低于对照组（P＜0.05）；两组PCNA阳性表达率较治疗前显著降低，且实验组低于对照组（P＜0.05）；两组不良反应发生率无差异（P＞0.05）。结论：重组人血管内皮抑素在骨肉瘤术后化疗中的效果显著，可调节血管内皮细胞平衡，降低VEGF水平以及PCNA阳性表达率，减少细胞增殖，提高PTEN水平，增强抑制恶性肿瘤细胞作用。 |
| 英文摘要: |
| ABSTRACT Objective: To study efficacy of recombinant human endostatin in postoperative chemotherapy for osteosarcoma and its effects on vascular endothelial growth factor (VEGF), pr oliferating cell nuclear antigen(PCNA), phosphatase and tensin homolog deleted in chromosome10 (PTEN). Methods: 220 patients of osteosarcoma who received therapy from March 2014 to March 2016 in our hospital were selected as research objects. According to the draw method divided into control group and experimental group, all the 110 cases. The control group was treated with DIA chemotherapy regimen, Intravenous infusion of cisplatin, ifosfamide, adriamycin. while the ob- servation group was based on the control group, treated with endostatin, Intravenous infusion of 15mg each time. The two groups were treated for 2 courses. Then The curative effect, limb function evaluation, VEGF and PTEN levels, the positive rate of PCNA, the inci- dence of adverse reactions of two groups were compared. Results: The total effective rate of the experimental group was significantly higher than that of the control group[81.81%（90/110）vs65.45%（72/110）]（P＜0.05）（P＜0.05）; The excellent rate of limb function in the experimental group was significantly higher than that in the control group [79.09%（87/110）vs63.63%（70/110）]（P＜0.05）; The PTEN levels in the two groups were significantly higher than those before treatment, but no difference was found（P＞0.05）, The VEGF levels of the two groups were significantly lower than those before treatment（P＜0.05）, the experimental group was lower than the con- trol group（P＜0.05）; The positive rate of PCNA in the two groups was significantly lower than that before treatment（P＜0.05）, the ex- perimental group was lower than the control group（P＜0.05）; There was no difference in the incidence of adverse reactions between the two groups（P＞0.05）. Conclusion: rh-endostatin is well for osteosarcoma, which can adjust the balance of vascular endothelial cells, de- crease the level of VEGF and the rate of PCNA positive expression, decrease the proliferation of cells, increase the level of PTEN, and inhibit the action of malignant tumor cells. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
